Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02771301 : Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas
PhaseN/A
AgesMin: 18 Years Max: 70 Years
Eligibility
Inclusion Criteria:

- The patient signed "informed consent" voluntarily;

- The age of patient is between 18 and 70 years;

- The tumor can be resected and tumor resection rate =80%;

- IDH1R132H mutation can be confirmed by immunohistochemistry or real-time quantitative
PCR;

- Peripheral blood lymphocytes absolute value is not less than 0.8 × 106;

- KPS score =70 ;

- The patient has normal bone marrow reserve and normal liver and kidney function ( The
bone marrow, liver and kidney function must be confirmed by Laboratory examination to
meet the requirements of participating in the study within 3 days before the first
acceptance of IDH1R132H-DC tumor vaccine therapy): Medium neutrophil absolute value
=1,500 / mm3; hemoglobin> 10g / dL; platelet count> 100,000 / mm3; total bilirubin
<1.5 × ULN; alanine aminotransferase / aspartate aminotransferase <2.5 × ULN; serum
creatinine <1.5 × ULN;

- Normal heart function ;

- Better follow-up and compliance;

- For women of childbearing age (15 to 49 years),pregnancy test must be negative 7 days
before starting this study. Male and female patients of childbearing potential must
agree to use effective contraceptive measures to ensure that during the study period
and three months after cessation of treatment will not be pregnant.

Exclusion Criteria:

- The patient did not sign "informed consent" or signed unvoluntarily.

- Non-glioma patients

- Drugs for brain or antibody therapy had been used 4 weeks before the start of this
study

- Active infection

- Human immunodeficiency virus (HIV) positive

- Hepatitis C or hepatitis B infective

- Pregnancy or breast-feeding women

- Patients did not agree to use effective contraception during treatment and the
following 3 months.

- Patients also participated in other clinical studies.

- The subjects researchers believe are not suitable for participation or completion of
the study.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02771301      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740